YIH
NKTR icon

Y-Intercept (HK)’s Nektar Therapeutics NKTR Stock Holding History

Y-Intercept (HK)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,545
Closed -$1.91M – 2023
2026
Q1 		$1.91M Buy
26,545
+15,683
+144% +$893K 0.04% 736
2025
Q4 		$459K Buy
+10,862
New +$608K 0.01% 1256
2024
Q2 		– Sell
-8,504
Closed -$119K – 1743
2024
Q1 		$119K Buy
+8,504
New +$89K 0.01% 1260
2023
Q3 		– Sell
-20,800
Closed -$179K – 1414
2023
Q2 		$179K Buy
+20,800
New +$222K 0.02% 955
2021
Q4 		– Sell
-712
Closed -$192K – 784
2021
Q3 		$192K Buy
+712
New +$171K 0.03% 585
2021
Q1 		– Sell
-1,083
Closed -$291K – 736
2020
Q4 		$291K Buy
+1,083
New +$280K 0.12% 321

Other funds holding NKTR

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Y-Intercept (HK)'s NKTR Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 26,545 shares — an estimated $1.91M sold.

Y-Intercept (HK) first reported a position in NKTR in Q4 2020 and held it in 6 quarters. The position peaked at $1.91M in Q1 2026. 11 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 26,545 Nektar Therapeutics shares in Q2 2026, an estimated $1.91M.
  • Y-Intercept (HK) first reported a position in Nektar Therapeutics in Q4 2020 and held it in 6 quarters.
  • Y-Intercept (HK)'s Nektar Therapeutics position peaked at $1.91M in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.